Anti-PD 1 Drug Active in Extensive SCLC (CME/CE)

(MedPage Today) -- Pembrolizumab provided 33% response rate in poor-prognosis disease
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news